Drugs / NUV-868
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT05252390 | Mar 2022 → Jul 2024 | malignant pancreatic neoplasm, ovarian carcinoma, prostate carcinoma, triple-negative breast carcinoma | Nuvation Bio Inc. | Terminated | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | NUV-868 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05252390 ↗ |
| Route | Oral | “NUV-868 is an investigational drug for oral dosing.” NCT05252390 ↗ |